What's Behind Incyte's Better-Than-Expected Q4 Earnings
Several products contributed to the biotech's solid growth.
Incyte(INCY)
Nasdaq Global Select
INCY
$77.50
$1.48
1.9%
Price as of March 4, 2021, 9:00 p.m. EST
View Interactive INCY Charts
The Company is a drug discovery and development company focused on developing proprietary small molecule drugs to treat serious unmet medical needs.
Interactive Chart
News & Analysis: Incyte
The Fool has written over 200 articles on Incyte.
Incyte Corp (INCY) Q4 2020 Earnings Call Transcript
INCY earnings call for the period ending February 9, 2021.
![The_Biggest_Drug_Competition_in_2021_Hint-_It_Isn_t_COVID_Vaccines[1]](https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F608752%2Fthe_biggest_drug_competition_in_2021_hint-_it_isn_t_covid_vaccines1.jpg&w=479&h=281&op=resize)
The Biggest Drug Competition in 2021 (Hint: It Isn't COVID Vaccines)
Investors should take notice of this four-way competition.
Incyte Corp (INCY) Q3 2020 Earnings Call Transcript
INCY earnings call for the period ending September 30, 2020.
Incyte Corp (INCY) Q2 2020 Earnings Call Transcript
INCY earnings call for the period ending June 30, 2020.
Here's Why Incyte Rose 19.1% in the First Half of 2020
Incyte might finally be convincing Wall Street that its pipeline is the real deal.
Incyte Corp (INCY) Q1 2020 Earnings Call Transcript
INCY earnings call for the period ending March 31, 2020.
Why Incyte's Q1 Loss Isn't As Bad As It Looks
The biotech's revenue increased solidly in Q1. And it had a very good explanation for its net loss.
Incyte Reports a Q1 Loss Due to MorphoSys Deal
The biotech's revenue soared thanks to the continued success of Jakafi, but its bottom line was weighed down by a licensing deal.
Is Incyte Stock a Buy?
Is the biotech company worth its rich valuation metrics?
